Oncology News Central Peer-Spectives

Keytruda RCC Approval/I-O – Toni Choueiri, MD, and Robert Figlin, MD, discuss the recent Keytruda approval in renal cell carcinoma (RCC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss Keytruda's approval in renal cell carcinoma (RCC).

Renal Cell Carcinoma (RCC) – Rana McKay, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GU 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Rana McKay, Assistant Professor of Medicine, University of California San Diego, discuss renal cell carcinoma (RCC) clinical highlights from ASCO GU 2019

Colorectal Cancer (CRC) – Axel Grothey, MD, and Robert Figlin, MD, provide clinical update in CRC

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Axel Grothey, MD, Director of GI Research, West Cancer Center, University of Tennessee, discuss new data from the BEACON study and the role of I-O and HIPEC in colorectal cancer

Hepatocellular Carcinoma (HCC) – Richard Finn, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GI 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Richard Finn, MD, Professor of Medicine at the Geffen School of Medicine, UCLA, discuss hepatocellular carcinoma (HCC) clinical highlights from ASCO GI 2019

Biliary Tract and GE Junction Cancers – Tanios Bekaii-Saab, MD, FACP, and Robert Figlin, MD, discuss clinical highlights from ASCO GI 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Tanios Bekaii-Saab, MD, Professor, Mayo Clinic College of Medicine and Science, discuss biliary tract and GE junction cancer clinical highlights from ASCO GI 2019

CAR-T Cell Therapy – Frederick Locke, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Frederick Locke, MD, Program Co-Leader, Immunology, Moffitt Cancer Center discuss CAR-T clinical highlights from ASH 2018

Multiple Myeloma – Sagar Lonial, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Sagar Lonial, MD, Professor and Chair, Hematology & Medical Oncology, Chief Medical Officer, Winship Cancer Institute of Emory University, discuss ALCYONE, GRIFFIN, and maintenance therapy (TOURMALINE-MM3), and other multiple myeloma clinical studies presented at the American Society of Hematology 2018 meeting

Breast Cancer – Debu Tripathy, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson, discuss IMpassion130, SOLAR-1 and other breast cancer clinical studies presented at the meeting

Head & Neck Cancer – Barbara Burtness, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Barbara Burtness, MD, Professor of Medicine (Medical Oncology) at the Yale University School of Medicine, discuss Keynote-048 and other H&N clinical studies presented at the meeting

Ovarian Cancer – Bradley Monk, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss BRCA1+ ovarian patients, PARP inhibitors and the results of the SOLO-1 clinical trial